Biogen ‘continues to work’ with FDA on Alzheimer's drug candidate despite regulatory setback

Biogen ‘continues to work’ with FDA on Alzheimer's drug candidate despite regulatory setback

Submitted by admin on November 10, 2020 - 10:36am
Source: 
Biopharma Reporter
News Tags: 
Biogen
FDA
Alzheimer's disease
aducanumab
Headline: 
Biogen ‘continues to work’ with FDA on Alzheimer's drug candidate despite regulatory setback
snippet: 

Biogen Inc’s shares tumbled around 30% yesterday with the company hitting a roadblock late last week as it chases regulatory approval for its investigational Alzheimer's treatment.

Do Not Allow Advertisers to Use My Personal information